AU2019377749B2 - Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor - Google Patents

Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor Download PDF

Info

Publication number
AU2019377749B2
AU2019377749B2 AU2019377749A AU2019377749A AU2019377749B2 AU 2019377749 B2 AU2019377749 B2 AU 2019377749B2 AU 2019377749 A AU2019377749 A AU 2019377749A AU 2019377749 A AU2019377749 A AU 2019377749A AU 2019377749 B2 AU2019377749 B2 AU 2019377749B2
Authority
AU
Australia
Prior art keywords
cells
transplantation
pharmaceutically acceptable
acceptable salt
rejection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019377749A
Other languages
English (en)
Other versions
AU2019377749A2 (en
AU2019377749A1 (en
Inventor
Keun-Hyung CHO
Mi-La Cho
Jong-Young Choi
Joo-Yeon Jhun
Se-Young Kim
Seon-Yeong Lee
Min-Jung PAKR
Sung-Hwan Park
Jae-Yoon RYU
Hyeon-Beom Seo
Dong-Yun Shin
Chul-Woo Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Industry Academic Cooperation Foundation of Catholic University of Korea
Original Assignee
Industry Academic Cooperation Foundation of Catholic University of Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industry Academic Cooperation Foundation of Catholic University of Korea filed Critical Industry Academic Cooperation Foundation of Catholic University of Korea
Publication of AU2019377749A1 publication Critical patent/AU2019377749A1/en
Publication of AU2019377749A2 publication Critical patent/AU2019377749A2/en
Application granted granted Critical
Publication of AU2019377749B2 publication Critical patent/AU2019377749B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019377749A 2018-11-07 2019-11-07 Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor Active AU2019377749B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020180136107A KR102147802B1 (ko) 2018-11-07 2018-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
KR10-2018-0136107 2018-11-07
PCT/KR2019/015055 WO2020096371A1 (ko) 2018-11-07 2019-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물

Publications (3)

Publication Number Publication Date
AU2019377749A1 AU2019377749A1 (en) 2021-05-27
AU2019377749A2 AU2019377749A2 (en) 2021-06-03
AU2019377749B2 true AU2019377749B2 (en) 2024-10-03

Family

ID=70612506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019377749A Active AU2019377749B2 (en) 2018-11-07 2019-11-07 Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

Country Status (8)

Country Link
US (1) US11969397B2 (https=)
EP (1) EP3878443A4 (https=)
JP (1) JP7470683B2 (https=)
KR (1) KR102147802B1 (https=)
CN (1) CN113194936A (https=)
AU (1) AU2019377749B2 (https=)
CA (1) CA3118881A1 (https=)
WO (1) WO2020096371A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554139B2 (en) * 2019-05-17 2023-01-17 Tolerogenixx Gmbh MIC therapy for specific immunosuppression in transplantation
CN115843745A (zh) * 2021-09-26 2023-03-28 泰州迈博太科药业有限公司 一种人源化肠炎小鼠模型的构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US10369121B2 (en) 2013-08-23 2019-08-06 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
JP6462002B2 (ja) 2014-04-29 2019-01-30 ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション 免疫疾患治療効果を有する新規化合物およびその使用
WO2015167243A1 (ko) * 2014-04-29 2015-11-05 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101613371B1 (ko) 2014-11-10 2016-04-18 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR20180038355A (ko) 2016-10-06 2018-04-16 서울과학기술대학교 산학협력단 탄성 및 기계적 물성이 우수한 탄성 고분자-세라믹 하이브리드 필름 및 이의 제조방법
KR20190045513A (ko) 2017-10-24 2019-05-03 가톨릭대학교 산학협력단 Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
US20220031637A1 (en) 2022-02-03
EP3878443A4 (en) 2022-08-24
WO2020096371A1 (ko) 2020-05-14
US11969397B2 (en) 2024-04-30
JP7470683B2 (ja) 2024-04-18
EP3878443A1 (en) 2021-09-15
AU2019377749A2 (en) 2021-06-03
CN113194936A (zh) 2021-07-30
CA3118881A1 (en) 2020-05-14
KR102147802B1 (ko) 2020-08-25
KR20200052743A (ko) 2020-05-15
JP2022513590A (ja) 2022-02-09
AU2019377749A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Gazdic et al. Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury
KR101480362B1 (ko) Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
US11793865B2 (en) Cultured phagocyte supernatent compositions
KR101723265B1 (ko) mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
US20080305079A1 (en) Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
KR20140117244A (ko) 조절 t 세포로의 분화 유도 및 증식 촉진을 통한 면역 반응 억제용 약학 조성물
AU2019377749B2 (en) Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
WO2011021833A2 (ko) 염증 예방 또는 치료용 조성물
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
CA2648889C (en) Use of thymosin alpha 1 for the treatment of immunological diseases
US11944601B2 (en) Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation
KR101705378B1 (ko) 간엽줄기세포 및 ⅰｌ-21 차단제를 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
KR101932840B1 (ko) 용해성 ｐｄ－ｌ１이 처리된 면역조절능을 갖는 골수유래억제세포 및 이의 용도
KR102237646B1 (ko) 타크롤리무스 및 비타민d를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CN103896812A (zh) N，n’－二环己基－n－高级脂肪酸酰脲类似物及其制药用途

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 28 APR 2021

FGA Letters patent sealed or granted (standard patent)